Results from Phase 3 study evaluating masitinib in prostate cancer
26/05/2021 – AB Science communicated the results from Phase 3 study evaluating masitinib in prostate cancer during the webcast that was held on May 25, 2021
Masitinib in Prostate Cancer Webcast Presentation
25/05/2021 – Presentation of the webcast held on May 25, 2021 on masitinib in prostate Cancer Download PDF
Live webcast on Tuesday May 25, 2021 on masitinib’s results in prostate cancer
21/05/2021 – AB Science will host a live webcast on May 25, 2021 to discuss recently reported results from the Phase 2B/3 masitinib trial in prostate cancer
Results from masitinib study AB12005 in pancreatic cancer selected for presentation at the ASCO Annual Meeting
20/05/2021 – AB Science today announced that results from masitinib study AB12005 in pancreatic cancer, have been selected for presentation at the upcoming ASCO Annual Meeting
Annual financial results as of 31 December, 2020
30/04/2021 – AB Science reports its annual financial results as of 31 December, 2020
Masitinib Phase 2B/3 study in prostate cancer met its primary endpoint
29/04/2021 – AB Science today announces that its masitinib Phase 2B/3 study (AB12003) in metastatic castrate-resistant prostate cancer (mCRPC) met its predefined primary endpoint
AB Science secures 6M€ in non-dilutive financing guaranteed by the French Government
14/04/2021 – AB Science today announces that it has received financing approval from Société Générale, Bpifrance and Banque Populaire for a total of EUR 6 million in the form of state-guaranteed loans
Signing of an exclusive licensing agreement with the University of Chicago to conduct research for the prevention and treatment of Covid-19
06/04/2021 – AB Science announces the signing of an exclusive licensing agreement with the University of Chicago to conduct research for the prevention and treatment of Covid-19
Update on masitinib Phase 3 study in prostate cancer
31/03/2021 – AB Science provides an update on the expected timelines for the read-out of its masitinib Phase 3 study (AB12003) in metastatic castrate-resistant prostate cancer
A new independent publication confirms the role of masitinib as a potential therapy in neurodegenerative disorders
08/03/2021 – AB Science announces that a new independent publication confirms the role of masitinib as a potential therapy in neurodegenerative disorders including Alzheimer’s Disease